Advertisement

Very early response of circulating tumour–derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non–small cell lung cancer

Published:October 25, 2017DOI:https://doi.org/10.1016/j.ejca.2017.09.004

      Highlights

      • First study to predict efficacy of immunotherapy by weekly changes of ctDNA after the treatment.
      • Only the analysis of plasma DNA lack specificity as ctDNA.
      • Analysis of plasma DNA was taken proof as ctDNA by the analysis of tumor tissue.
      • Efficacy of immunotherapy can be predicted within early periods by the use of circulating tumour DNA.

      Abstract

      Introduction

      Immunotherapy has become a treatment option for lung cancer. The utility of nivolumab as second-line treatment for non–small cell lung cancer has been proven, but predictive biomarkers influencing its efficacy remain unknown.

      Methods

      This study involved 14 patients who were treated with nivolumab from February 1 to September 30, 2016. The early response of the level of circulating tumour DNA (ctDNA) after starting nivolumab was evaluated to ascertain whether it could predict treatment outcome.

      Results

      Of the 14 patients, six were responders and eight were non-responders. DNA was analysed in both tumour tissue and plasma samples. Only somatic mutations confirmed by analysis of tumour tissue were defined as ctDNA. ctDNA was detected more often in the serial plasma samples of patients with high tumour volume (TV) (p = 0.02). ctDNA was detected in seven cases; basal and serial ctDNA analysis revealed that a decrease in allelic frequency (AF) of ctDNA showed high-level correspondence with a good durable response. When “2 weeks” was set as a clinically significant time point, changes in representative mutations of each case, defined as one of the highest baseline AF, showed 100% concordance with the response.

      Conclusions

      In patients with high TV, plasma analysis of ctDNA, as validated by tumour tissue, suggested that a durable good response to nivolumab could be predicted within 2 weeks.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • McCarthy E.F.
        The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.
        Iowa Orthop J. 2006; 26: 154-158
        • Leach D.R.
        • Krummel M.F.
        • Allison J.P.
        Enhancement of antitumor immunity by CTLA-4 blockade.
        Science. 1996; 271: 1734-1736
        • Wolchok J.D.
        • Neyns B.
        • Linette G.
        • Negrier S.
        • Lutzky J.
        • Thomas L.
        • et al.
        Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
        Lancet Oncol. 2010; 11: 155-164
        • Robert C.
        • Long G.V.
        • Brady B.
        • Dutriaux C.
        • Maio M.
        • Mortier L.
        • et al.
        Nivolumab in previously untreated melanoma without BRAF mutation.
        N Engl J Med. 2015; 372: 320-330
        • Larkin J.
        • Chiarion-Sileni V.
        • Gonzalez R.
        • Grob J.J.
        • Cowey C.L.
        • Lao C.D.
        • et al.
        Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.
        N Engl J Med. 2015; 373: 23-34
        • Topalian S.L.
        • Hodi F.S.
        • Brahmer J.R.
        • Gettinger S.N.
        • Smith D.C.
        • McDermott D.F.
        • et al.
        Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
        N Engl J Med. 2012; 366: 2443-2454
        • Rizvi N.A.
        • Mazières J.
        • Planchard D.
        • Stinchcombe T.E.
        • Dy G.K.
        • Antonia S.J.
        • et al.
        Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2, single-arm trial.
        Lancet Oncol. 2015; 16: 257-265
        • Brahmer J.
        • Reckamp K.L.
        • Baas P.
        • Crinò L.
        • Eberhardt W.E.
        • Poddubskaya E.
        • et al.
        Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.
        N Engl J Med. 2015; 373: 123-135
        • Borghaei H.
        • Paz-Ares L.
        • Horn L.
        • Spigel D.R.
        • Steins M.
        • Ready N.E.
        • et al.
        Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer.
        N Engl J Med. 2015; 373: 123-135
        • Reck M.
        • Rodríguez-Abreu D.
        • Robinson A.G.
        • Hui R.
        • Csőszi T.
        • Fülöp A.
        • et al.
        Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.
        N Engl J Med. 2016; 375: 1823-1833
        • Fehrenbacher L.
        • Spira A.
        • Ballinger M.
        • Kowanetz M.
        • Vansteenkiste J.
        • Mazieres J.
        • et al.
        Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
        Lancet. 2016; 387: 1837-1846
        • Brahmer J.R.
        • Tykodi S.S.
        • Chow L.Q.
        • Hwu W.J.
        • Topalian S.L.
        • Hwu P.
        • et al.
        Safety and activity of anti–PD-L1 antibody in patients with advanced cancer.
        N Engl J Med. 2012; 366: 2455-2465
        • Lipson E.J.
        • Sharfman W.H.
        • Drake C.G.
        • Wollner I.
        • Taube J.M.
        • Anders R.A.
        • et al.
        Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody.
        Clin Cancer Res. 2013; 19: 462-468
        • Hodi F.S.
        • O'Day S.J.
        • McDermott D.F.
        • Weber R.W.
        • Sosman J.A.
        • Haanen J.B.
        • et al.
        Improved survival with ipilimumab in patients with metastatic melanoma.
        N Engl J Med. 2010; 363: 711-723
        • Topalian S.L.
        • Sznol M.
        • McDermott D.F.
        • Kluger H.M.
        • Carvajal R.D.
        • Sharfman W.H.
        • et al.
        Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
        J Clin Oncol. 2014; 32: 1020-1030
        • Newman A.M.
        • Bratman S.V.
        • To J.
        • Wynne J.F.
        • Eclov N.C.
        • Modlin L.A.
        • et al.
        An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.
        Nat Med. 2014; 20: 548-554
        • Diehl F.
        • Schmidt K.
        • Choti M.A.
        • Romans K.
        • Goodman S.
        • Li M.
        • et al.
        Circulating mutant DNA to assess tumor dynamics.
        Nat Med. 2008; 14: 985-990
        • Sirera R.
        • Bremnes R.M.
        • Cabrera A.
        • Jantus-Lewintre E.
        • Sanmartín E.
        • Blasco A.
        • et al.
        Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
        J Thorac Oncol. 2011; 6: 286-290
        • Gautschi O.
        • Bigosch C.
        • Huegli B.
        • Jermann M.
        • Marx A.
        • Chassé E.
        • et al.
        Circulating deoxyribonucleic acid as prognostic marker in non–small-cell lung cancer patients undergoing chemotherapy.
        J Clin Oncol. 2004; 22: 4157-4164
        • Nygaard A.D.
        • Holdgaard P.C.
        • Spindler K.L.
        • Pallisgaard N.
        • Jakobsen A.
        The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC.
        Br J Cancer. 2014; 110: 363-368
        • Kumar S.
        • Guleria R.
        • Singh V.
        • Bharti A.C.
        • Mohan A.
        • Das B.C.
        Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer.
        Eur Respir J. 2010; 36: 885-892
        • Murtaza M.
        • Dawson S.J.
        • Tsui D.W.
        • Gale D.
        • Forshew T.
        • Piskorz A.M.
        • et al.
        Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.
        Nature. 2013; 497: 108-112
        • Del Re M.
        • Vasile E.
        • Falcone A.
        • Danesi R.
        • Petrini I.
        Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
        Expert Rev Mol Diagn. 2014; 14: 453-468
        • Sozzi G.
        • Conte D.
        • Leon M.
        • Ciricione R.
        • Roz L.
        • Ratcliffe C.
        • et al.
        Quantification of free circulating DNA as a diagnostic marker in lung cancer.
        J Clin Oncol. 2003; 21: 3902-3908
        • Kim K.
        • Shin D.G.
        • Park M.K.
        • Baik S.H.
        • Kim T.H.
        • Kim S.
        • et al.
        Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection.
        Ann Surg Treat Res. 2014; 86: 136-142
        • Li B.T.
        • Drilon A.
        • Johnson M.L.
        • Hsu M.
        • Sima C.S.
        • McGinn C.
        • et al.
        A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.
        Ann Oncol. 2016; 27: 154-159
        • Wolchok J.D.
        • Hoos A.
        • O'Day S.
        • Weber J.S.
        • Hamid O.
        • Lebbé C.
        • et al.
        Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
        Clin Cancer Res. 2009; 15: 7412-7420
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • Schwartz L.H.
        • Sargent D.
        • Ford R.
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1·1).
        Eur J Cancer. 2009; 45: 228-247
        • Goto T.
        • Hirotsu Y.
        • Mochizuki H.
        • Nakagomi T.
        • Shikata D.
        • Yokoyama Y.
        • et al.
        Mutational analysis of multiple lung cancers: discrimination between primary and metastatic lung cancers by genomic profile.
        Oncotarget. 2017 Mar 10; https://doi.org/10.18632/oncotarget.16096
        • Sakamoto I.
        • Hirotsu Y.
        • Nakagomi H.
        • Ouchi H.
        • Ikegami A.
        • Teramoto K.
        • et al.
        BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer.
        Cancer. 2016; 122: 84-90
        • TCGA
        Comprehensive molecular profiling of lung adenocarcinoma.
        Nature. 2014; 511: 543-550
        • TCGA
        Comprehensive genomic characterization of squamous cell lung cancers.
        Nature. 2012; 489: 519-525
        • Goto T.
        • Hirotsu Y.
        • Oyama T.
        • Amemiya K.
        • Omata M.
        Analysis of tumor-derived DNA in plasma and bone marrow fluid in lung cancer patients.
        Med Oncol. 2016; 33: 29
        • Reck M.
        • Rodríguez-Abreu D.
        • Robinson A.G.
        • Hui R.
        • Csőszi T.
        • Fülöp A.
        • et al.
        Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.
        N Engl J Med. 2016 Nov 10; 375: 1823-1833
        • Ilie M.
        • Long-Mira E.
        • Bence C.
        • Butori C.
        • Lassalle S.
        • Bouhlel L.
        • et al.
        Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.
        Ann Oncol. 2016; 27: 147-153
        • Carbone D.P.
        • Reck M.
        • Paz-Ares L.
        • Creelan B.
        • Horn L.
        • Steins M.
        • et al.
        First-line nivolumab in stage IV or recurrent non-small-cell lung cancer.
        N Engl J Med. 2017; 376: 2415-2426
        • Lipson E.J.
        • Velculescu V.E.
        • Pritchard T.S.
        • Sausen M.
        • Pardoll D.M.
        • Topalian S.L.
        • et al.
        Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade.
        J Immunother Cancer. 2014; 2: 42
        • Gray E.S.
        • Rizos H.
        • Reid A.L.
        • Boyd S.C.
        • Pereira M.R.
        • Lo J.
        • et al.
        Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
        Oncotarget. 2015; 6: 42008-42018
        • Lee J.H.
        • Long G.V.
        • Boyd S.
        • Lo S.
        • Menzies A.M.
        • Tembe V.
        • et al.
        Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
        Ann Oncol. 2017; 28: 1130-1136
        • Cabel L.
        • Riva F.
        • Servois V.
        • Livartowski A.
        • Daniel C.
        • Rampanou A.
        • et al.
        Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study.
        Ann Oncol. 2017;Apr 29; https://doi.org/10.1093/annonc/mdx212